Related Experiment Video
Updated: Jun 28, 2026

09:11
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
Published on: April 9, 2019
22.6K
mpMRI-Based Risk Estimation to Optimize Prostate Cancer Patient Selection for Active Surveillance
Veronica Wallaengen1,2, Evangelia I Zacharaki1, Mohammad Alhusseini1
1Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Cancers
|March 14, 2026
Summary
A new risk assessment platform accurately predicts prostate cancer (PCa) progression within 12 months. This tool improves active surveillance (AS) by identifying patients needing immediate treatment versus those suitable for monitoring.
Area of Science:
- Oncology
- Radiology
- Medical Imaging
Background:
- Active surveillance (AS) is a viable option for low-risk prostate cancer (PCa).
- Current risk stratification tools are insufficient for optimal AS patient selection.
- Early detection of PCa progression is crucial for effective management.
Purpose of the Study:
- To develop an integrated method for predicting PCa progression within 12 months.
- To enhance patient selection for AS by categorizing individuals into rapid and slow progressors.
- To improve the safety and efficacy of AS strategies.
Main Methods:
- Utilized convolutional neural networks for multiparametric MRI (mpMRI) lesion segmentation.
- Integrated mpMRI radiomics with clinical variables (age, PSA, PI-RADS) for risk prediction.
- Trained models on radical prostatectomy data mapped to mpMRI and prospectively validated on 163 participants.
Main Results:
- The clinical-radiomics model achieved an AUC of 0.84 in predicting progression.
- The model significantly improved AS patient selection in an independent test set.
- Negative predictive value increased by 18.5% compared to standard care (p < 0.001).
Conclusions:
- The risk assessment platform reliably differentiates AS candidates with stable disease from those likely to progress early.
- This tool shows promise for use during annual follow-up visits.
- Improved risk stratification can optimize AS management for prostate cancer patients.

